コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 alcohol, smoking, race, and BMI (for WC and type II diabetes mellitus).
2 tance and glucose toxicity, the hallmarks of type II diabetes mellitus.
3 k of thrombosis, such as atherosclerosis and type II diabetes mellitus.
4 its disruption can cause hyperglycaemia and type II diabetes mellitus.
5 potential therapeutics for the treatment of type II diabetes mellitus.
6 tial for hypoglycaemic risk in patients with type II diabetes mellitus.
7 one of the key targets in the management of type II diabetes mellitus.
8 accomplish glycemic targets in patients with type II diabetes mellitus.
9 ted risk of obesity, metabolic syndrome, and type II diabetes mellitus.
10 constituent of islet amyloid, a hallmark of type II diabetes mellitus.
11 n important drug target for the treatment of Type II diabetes mellitus.
12 in the activation loop of the IR that causes type II diabetes mellitus.
13 lay an important role in the pathogenesis of type II diabetes mellitus.
14 cute lung injury is reduced in patients with type II diabetes mellitus.
15 ) and its toxicity, which is associated with type II diabetes mellitus.
16 ontrol of gluconeogenesis and progression to type II diabetes mellitus.
17 allel with increasing trends for obesity and type II diabetes mellitus.
18 e, sleep apnea, obesity hypoventilation, and type II diabetes mellitus.
19 on defects are central to the development of type II diabetes mellitus.
20 lium-dependent vasodilation in patients with type II diabetes mellitus.
21 f its role in lipid metabolism, obesity, and type II diabetes mellitus.
22 y the Federal Drug Administration for use in type II diabetes mellitus.
23 insulin resistance, and an earlier onset of type II diabetes mellitus.
24 to the impaired insulin secretion in severe type II diabetes mellitus.
25 polymorphisms in PROMIS were associated with type II diabetes mellitus.
26 drugs for the treatment of human obesity and type II diabetes mellitus, a series of 1-(3, 5-diiodo-4-
27 use, hypercholesterolemia, hypertension, and type II diabetes mellitus all contribute to the risk of
28 ith chronic kidney disease stage five due to type II diabetes mellitus and hypertension was referred
30 its in the pancreatic islets of sufferers of type II diabetes mellitus, and its self-aggregation is t
31 bute to the insulin resistance of pregnancy, type II diabetes mellitus, and other pathological condit
32 , and all with sleep apnea, hypoventilation, type II diabetes mellitus, and urinary incontinence.
33 ations seen in patients with both type I and type II diabetes mellitus are associated with alteration
34 s study suggests that high BMI, high WC, and type II diabetes mellitus are associated with higher ris
35 by inhalation) was blunted in patients with type II diabetes mellitus as compared with control subje
36 eotide polymorphism associations with MI and type II diabetes mellitus but these did not meet signifi
37 Genetic factors influence the development of type II diabetes mellitus, but genetic loci for the most
38 tical target in the treatment of obesity and type II diabetes mellitus, constrains the metabolic acti
40 comorbidities, including hypertension (HTN), type II diabetes mellitus, dyslipidemia, obstructive sle
41 ere significantly common among patients with type II diabetes mellitus (Fisher's exact test, p = 0.03
42 uding coronary artery disease, hypertension, type II diabetes mellitus, gallstones, nonalcoholic stea
43 widely prescribed as first-line treatment of type II diabetes mellitus, has lifespan-extending proper
45 so suggest that as a potential treatment for type II diabetes mellitus, increased skeletal muscle GLU
47 ty of insulin to suppress gluconeogenesis in type II diabetes mellitus is impaired; however, the cell
48 t diabetes of the young, a monogenic form of Type II diabetes mellitus, is most commonly caused by mu
49 ncidence and mortality from diseases such as type II diabetes mellitus, neurodegenerative diseases, c
52 ity, in patients with non-insulin-dependent (type II) diabetes mellitus, one contributor may be the u
53 es of the young (MODY3), a monogenic form of type II diabetes mellitus, results most commonly from mu
54 ation between snoring and risk of developing type II diabetes mellitus, the authors analyzed data fro
55 cokinase levels are known to cause a form of type II diabetes mellitus, these observations raise the
56 tal diseases, including Alzheimer's disease, type II diabetes mellitus, transmissible spongiform ence
58 s index (BMI), waist circumference (WC), and type II diabetes mellitus with risk of liver cancer.
59 endogenous ET-1 in a group of patients with type II diabetes mellitus with the use of antagonists of
60 key therapeutic target in the management of type II diabetes mellitus, with actions including regula
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。